ZLAB

Zai Lab is doing the hard part of a commercial biopharma turnaround well. Revenue has compounded from $144M (FY2021) to $457M (FY2025), up 15% last year, while the net loss has narrowed every single year — from -$704M in FY2021 to -$176M in FY2025 (+31.7% YoY). Operating cash burn improved ~30% to -$151M, and the balance sheet is in better shape than the income statement suggests: $680M cash (+51% YoY), current assets of $1.02B against $416M current liabilities (~2.45x current ratio), and a manageable 0.64x liabilities/equity. Management frames 2025 as 'strong financial performance,' with seven launched commercial products (ZEJULA, VYVGART, NUZYRA, OPTUNE, QINLOCK, XACDURO, AUGTYRO) and concrete near-term drivers — XACDURO and NUZYRA leading the revenue growth, plus fresh NMPA approvals of AUGTYRO (NTRK+ tumors) and KarXT (schizophrenia) in Q4 2025. This is a quality-improving story, not a deteriorating one.

The problem is the price, not the company. At $18.41 the market cap is $20.4B on $457M of revenue — a P/S of ~44.6x for a business still generating a -50.2% operating margin, a -38.4% net margin, and a -24.5% ROE, with -$2.63B of accumulated deficit. That multiple already discounts years of successful execution and pipeline conversion. The MD&A is candid that the company 'cannot predict whether or when' candidates win approval or turn profitable and expects to keep losing money 'for at least the next few quarters.' Note also that a clean FY2025 gross margin is not in the provided data (only a stale FY2018 gross-profit figure appears), so the headline 0.0% gross margin is a data artifact, not a real read — I'm not leaning on it either way.